

Understanding and predicting outcomes in kidney transplantation and immunosuppressive treatments

Data range for infographic: 01.01.2000-01.07.2022

Other extended time periods are available on request

A dataset to understand the knowledge base surrounding transplants and their long-term outcomes, and to improve patient well-being. This dataset could be used for traditional statistical or machine learning/ artificial intelligence methodologies.

Demographic

The dataset includes:

- Young adults **7%** (ages 15-24)
- Adults **81%** (ages 25-64)
- Older adults **12%** (ages 65+)

Based on the index of multiple deprivation map, **41%** of the population are from most deprived areas and **9%** of patients are from least deprived areas.

31% 8% **53%**





4%



4%

Asian Black African

White

Not

Caribbean

Other

Stated

Charlson Comorbidity Index at transplant

36%



Mild 1-2

42%



Moderate 3-4

Score

Diagnoses

Top 5 diagnoses in patient spell:

- **45K** Stage 5 chronic kidney disease
- **10K** Essential primary hypertension
- **3K** Type 2 diabetes mellitus
- **2K** Hypertensive renal disease
- 2K Complications of cardiac and vascular prosthetic devices, implants and grafts

28% **53%** 9% 10% 1%













No dialysis

Postdilution

Pre-

High flux Other filtration

22%

Severe

5+

Haemadiafiltration

dilution

59K haemadiafiltration (HDF) sessions attended with less than 2k sessions missed.

Other dialysis information are available.


Patients on immunosuppressive

99.9%

99.4%







Mycophenolate Adoport mofetil (BD tacrolimus)



 $\mathbf{0}\mathbf{0}\mathbf{0}\mathbf{0}$

Prednisolone

Nephrotoxicity

Percentage of patients with nephrotoxicity within 5 year of transplant is less than 1%.


Other medications are available.

Inpatient care

- **79,698 Hospitalised spells;** containing **868** unique patients who had a kidney transplant
- **123K** days worth of hospital data with an average in-hospital length of stay of 1 day
- Average readmission rate of 14 times per year and hospital mortality rate of less than 1% Less than 1% of patients had a major adverse cardiovascular event prior kidney transplant

Thromboemmolism

1% of patients had a thromboembolic event prior to kidney transplant and less than 2% had a thromboembolic event within 5 years of kidney transplant.



Post transplant comorbidity

4% of patients had new diabetes within 5 years of transplant and 6% of patients had new malignant tumors within 5 years of transplant.

